Article · 30 Sep 2024
Research articlePublished 2015
Algorithm for Selecting Ideal Biologic Treatment for Psoriasis
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Biologics are the standard treatment for moderate-to-severe psoriasis due to their efficacy and safety. However, the selection of appropriate biologics is complicated by patient characteristics, treatment regimen, and cost. We constructed an algorithm to select biologics based on psoriasis type (psoriasis vulgaris or psoriasis arthritis), Psoriasis Area and Severity Index (PASI) score (≥ 20 or <20) and body mass index (≥ 25 or <25). To validate our algorithm, we retrospectively analyzed 134 patients treated with biologics. Based on the algorithm, patients were categorized into the following treatment groups: infliximab-appropriate (IFX-ap), n=33; adalimumab-appropriate (ADA-ap), n=44; and ustekinumab-appropriate (UST-ap), n=57. The relationship between each agent-appropriate group and the efficacy of each agent was analyzed. Among IFX-ap patients (n=33), the reduction in PASI with each treatment was as follows: inflximab (n=13), 93.2 ± 7.4%; adalimumab (n=10), 61.3 ± 29.2%; and ustekinumab (n=10), 87.4 ± 12.8%, with significant differences between infliximab and adalimumab. Among ADA-ap patients (n=44), the reduction in PASI with each treatment was as follows: infliximab (n=10), 83.3 ± 23.3%; adalimumab (n=12), 84.9 ± 23.6%; and ustekinumab (n=14), 73.0 ± 29.8%, with no significant differences between treatments. Among UST-ap patients, the reduction in PASI with each treatment was as follows: infliximab (n=15), 94.9 ± 6.0%; adalimumab (n=14), 73.0 ± 23.0%; and ustekinumab (n=28), 87.2 ± 18.0%, with a significant difference between treatment with adalimumab and ustekinumab. These results suggest that appropriate biologics selection results in increased efficacy of treatment.
Subjects
DermatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 24 Nov 2023
Paradoxical Responses in Biologic Therapy for Psoriasis: Unraveling Mechanisms and Optimizing Treatment Strategies
Opinion · 12 May 2023
Advances in the treatment of psoriasis: biologic therapies
Conference abstract · 28 Jan 2019
Biological products pi-2a II-oral and topical treatment of pediatric psoriasis
Commentary · 21 Sep 2017
Commentary on “Experience and challenges for biologic use for the treatment of moderate-to-severe psoriasis in Africa and the Middle East region”
More from this journal
The newest in Journal of Clinical & Experimental Dermatology Research.
Research article · 30 Jul 2026
MINIMALLY-INVASIVE LASER-ASSISTED (MILA) FACELIFT UNDER LOCAL ANESTHESIA
Commentary · 30 Jul 2026
Breaking the Stigma Around Psoriasis: A Broader View of Chronic Skin Disease
Perspective · 28 Jul 2026
Acne as More Than a Cosmetic Concern: A Personal and Medical Perspective
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical & Experimental Dermatology Research
- SubjectDermatology
- BylineArticles whose byline prints “Yoshinori Umezawa”
- BylineArticles whose byline prints “Akihiko Asahina”
- BylineArticles whose byline prints “Sota Kikuchi”
- BylineArticles whose byline prints “Koichi Yanaba”
- BylineArticles whose byline prints “Hidemi Nakagawa”

